SE0104332D0 - Therapeutic agents - Google Patents
Therapeutic agentsInfo
- Publication number
- SE0104332D0 SE0104332D0 SE0104332A SE0104332A SE0104332D0 SE 0104332 D0 SE0104332 D0 SE 0104332D0 SE 0104332 A SE0104332 A SE 0104332A SE 0104332 A SE0104332 A SE 0104332A SE 0104332 D0 SE0104332 D0 SE 0104332D0
- Authority
- SE
- Sweden
- Prior art keywords
- iquest
- chloro
- therapeutic agents
- obesity
- psychiatric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Abstract
The present invention relates to compound of formula (I) and pharmaceutically acceptable salts, solvates and crystalline forms thereof, in which R¿1< represents cyclohexyl, 1-piperidinyl or phenyl; R¿2? represents H, chloro, bromo, methyl or methoxy; and when R¿3? represents H, R¿4? represents H or chloro; and when R¿3? represents chloro, R¿4? represents H or chloro; to processes for preparing such compounds, to their use in the treatment of obesity, psychiatric and neurological disorders particularly obesity, to methods for their therapeutic use and to pharmaceutical compositions containing them.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0104332A SE0104332D0 (en) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
AU2002352420A AU2002352420A1 (en) | 2001-12-19 | 2002-12-18 | Pyrazine compounds and pharmaceutical compositions containing them |
PCT/GB2002/005736 WO2003051850A1 (en) | 2001-12-19 | 2002-12-18 | Pyrazine compounds and pharmaceutical compositions containing them |
TW091136670A TW200410693A (en) | 2001-12-19 | 2002-12-19 | Therapeutic agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0104332A SE0104332D0 (en) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0104332D0 true SE0104332D0 (en) | 2001-12-19 |
Family
ID=20286431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0104332A SE0104332D0 (en) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU2002352420A1 (en) |
SE (1) | SE0104332D0 (en) |
TW (1) | TW200410693A (en) |
WO (1) | WO2003051850A1 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003082191A2 (en) | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
GB0302673D0 (en) | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
GB0314049D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
US20060135523A1 (en) * | 2003-06-18 | 2006-06-22 | Astrazeneca Ab | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator |
GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
EP1644370A4 (en) | 2003-07-11 | 2008-06-04 | Bristol Myers Squibb Co | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
WO2005037199A2 (en) | 2003-10-10 | 2005-04-28 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
BRPI0507120A (en) | 2004-01-28 | 2007-06-19 | Hoffmann La Roche | compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases that are associated with cb1 receptor modulation and their use |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
JP4675969B2 (en) | 2004-11-09 | 2011-04-27 | エフ.ホフマン−ラ ロシュ アーゲー | Dibenzosuberone derivatives |
DK1868999T3 (en) | 2005-04-06 | 2009-08-17 | Hoffmann La Roche | Pyridine-3-carboxamide derivatives as reverse CB1 agonists |
CA2606288A1 (en) * | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
PE20071320A1 (en) * | 2006-01-18 | 2007-12-29 | Schering Corp | CANNABINOID RECEPTOR MODULATORS |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
FR2904827B1 (en) * | 2006-08-11 | 2008-09-19 | Sanofi Aventis Sa | 5,6-BISARYL-2-PYRIDINE CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE AS UROTENSIN II RECEPTOR ANTIGANISTS |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
BRPI0717845A2 (en) | 2006-10-04 | 2015-06-16 | Hoffmann La Roche | Use of compounds, pharmaceutical compositions and methods for the treatment and / or prophylaxis of diseases that can be treated with HDL-cholesterol elevating agents and compounds. |
JP2010514828A (en) | 2007-01-04 | 2010-05-06 | プロシディオン・リミテッド | Piperidine GPCR agonist |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
EP2114936A1 (en) | 2007-01-04 | 2009-11-11 | Prosidion Limited | Piperidine gpcr agonists |
AR064735A1 (en) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | GPCR AGONISTS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND |
AR064736A1 (en) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | GPCR AGONISTS |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
FR2927330B1 (en) * | 2008-02-07 | 2010-02-19 | Sanofi Aventis | 5,6-BISARYL-2-PYRIDINE CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE AS ANTAGONISTS OF UROTENSIN II RECEPTORS |
WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989004308A1 (en) * | 1987-11-12 | 1989-05-18 | Terumo Kabushiki Kaisha | Pyrazine derivatives and medicinal preparation containing same |
JPH06501926A (en) * | 1990-08-06 | 1994-03-03 | 藤沢薬品工業株式会社 | heterocyclic compound |
-
2001
- 2001-12-19 SE SE0104332A patent/SE0104332D0/en unknown
-
2002
- 2002-12-18 AU AU2002352420A patent/AU2002352420A1/en not_active Abandoned
- 2002-12-18 WO PCT/GB2002/005736 patent/WO2003051850A1/en not_active Application Discontinuation
- 2002-12-19 TW TW091136670A patent/TW200410693A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW200410693A (en) | 2004-07-01 |
AU2002352420A1 (en) | 2003-06-30 |
WO2003051850A1 (en) | 2003-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0104332D0 (en) | Therapeutic agents | |
IS2293B (en) | Aryl fused azapolycyclic compounds | |
MXPA03011638A (en) | 4-piperazinylindole derivatives with 5-ht6 receptor affinity. | |
JO2371B1 (en) | 4-phenyl -pyridine derivatives | |
GEP20053600B (en) | 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors | |
RS28004A (en) | Azabicycle-substituted fused- heteroaryl compounds for the treatment of disease | |
YU95102A (en) | Substituted bicyclic derivatives for the treatment of abnormal cell growth | |
MXPA04000278A (en) | Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury. | |
HK1070054A1 (en) | Arylsulfonyl derivatives with5-ht6 receptor affinity | |
PL361361A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
SE0400043D0 (en) | New compounds | |
PL361282A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
TW200509933A (en) | Therapeutic agents | |
ATE268337T1 (en) | C11-CARBAMATES OF ANTIBACTERIAL MACROLIDS | |
EA200301203A1 (en) | NEW COMPOUNDS AND COMPOSITIONS AS KATEPSIN INHIBITORS | |
BG104983A (en) | Aryl fused azapolycyclic compounds | |
MXPA04005313A (en) | Aminotetralin derivatives as muscarinic receptor antagonists. | |
MXPA04005076A (en) | 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists. | |
DE69933885D1 (en) | TRIPHENYLBUTEN DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
CA2374643A1 (en) | 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists | |
IL153784A0 (en) | Novel n-(2-phenyl-3-aminopropyl) naphthamides | |
DE69911373D1 (en) | AZETIDINE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISEASES | |
AU2178199A (en) | Azetidinecarboxamide derivatives for the treatment of cns disorders | |
DK1049670T3 (en) | Azetidine carboxamide derivatives for the treatment of CNS disorders | |
YU79401A (en) | 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |